

# Case Study

## OCON Healthcare



*CIF Investment: October 2021*

**Imagine a non-invasive alternative to uterine ablation or hysterectomy, to treat heavy bleeding, performed in a doctor's office. Or, treatments for myomas/fibroids or endometriosis, with drugs delivered via the uterus, without systemic side effects.**

OCON Therapeutics is a **woman-led** company developing cutting-edge women's health innovations based on their **IUB®** (Intra Uterine Ball) platform. The IUB® can carry drugs to the uterus to treat a variety of conditions, including **abnormal uterine bleeding, heavy menstrual bleeding, myomas/fibroids, endometriosis and infertility.**

*20% of women are affected by Abnormal Menstrual Bleeding and/or Heavy Menstrual Bleeding*

*10% of women have endometriosis, which can cause infertility, pain, heavy bleeding and digestive problems*

*Heavy menstrual bleeding can cause anemia, and in 42% of affected women it leads to depression*

### Milestones, Results and Recognition

- **The World Economic Forum:** OCON named as Technology Pioneer - 2022
- **Entrepreneur Magazine: 100 Women of Influence:** Named OCON's CEO Keren Lesham to this list - 2022
- **Phase IIb Study of IUB SEAD® - Treatment for heavy menstrual bleeding**
  - **Fully Enrolled** - Spring 2023
  - **75% Avg Reduction in Bleeding** - Interim results

### Asset Milestones

Solution	Discovery	Research	Clinical Trials	Commercialization
<i>IUB Platform Technology</i>	✓	✓	<i>In Progress</i>	